Payment overview · 2025
General Payments
$727.14
7 reported records · 5 companies
Healthcare provider profile · identity verified
Jeffrey Mark Kagan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEWINGTON, CT · NPI 1003886193
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Mark Kagan, M.D. received $727.14 in general payments during 2025 across 7 reported records.
Axsome Therapeutics, Inc. accounted for 48.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 523 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $353.01 | 48.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.98 | 17.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $120.98 | 16.6% | 1 | 2025 |
| Biocomposites Inc | Unresolved — no canonical attribution shown | $94.94 | 13.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.23 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $727.14 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $353.01 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $120.98 | 1 | 2025 |
Source payment records
|
|||||
| Stimulan Normalized: stimulan |
Device | Biocomposites Inc | $94.94 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $33.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
108 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
523 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1734 | 263 |
| Levothyroxine Sodium | Levothyroxine Sodium | 873 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 860 | 131 |
| Lisinopril | Lisinopril | 833 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 751 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 706 | 97 |
| Mirtazapine | Mirtazapine | 669 | 47 |
| Gabapentin | Gabapentin | 654 | 74 |
| Trazodone Hcl | Trazodone Hcl | 560 | 72 |
| Eliquis | Apixaban | 523 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 517 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 501 | 44 |
| Sertraline Hcl | Sertraline Hcl | 466 | 38 |
| Losartan Potassium | Losartan Potassium | 463 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 458 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 87 |
| Omeprazole | Omeprazole | 327 | 48 |
| Potassium Chloride | Potassium Chloride | 318 | 33 |
| Furosemide | Furosemide | 317 | 48 |
| Metformin Hcl | Metformin Hcl | 311 | 47 |
| Donepezil Hcl | Donepezil Hcl | 293 | 31 |
| Simvastatin | Simvastatin | 270 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 269 | 31 |
| Memantine Hcl | Memantine Hcl | 262 | 15 |
| Divalproex Sodium | Divalproex Sodium | 231 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 210 | 50 |
| Torsemide | Torsemide | 203 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 197 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 50 |
| Buspirone Hcl | Buspirone Hcl | 185 | 19 |
| Baclofen | Baclofen | 170 | 19 |
| Jardiance | Empagliflozin | 168 | 24 |
| Levetiracetam | Levetiracetam | 167 | 13 |
| Metformin Hcl Er | Metformin Hcl | 165 | 33 |
| Ezetimibe | Ezetimibe | 162 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 162 | 14 |
| Tradjenta | Linagliptin | 160 | 17 |
| Atenolol | Atenolol | 159 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 152 | 15 |
| Finasteride | Finasteride | 151 | 26 |
| Methenamine Hippurate | Methenamine Hippurate | 149 | suppressed |
| Allopurinol | Allopurinol | 144 | 33 |
| Bupropion Xl | Bupropion Hcl | 137 | suppressed |
| Risperidone | Risperidone | 132 | suppressed |
| Alprazolam | Alprazolam | 125 | 30 |
| Montelukast Sodium | Montelukast Sodium | 124 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 114 | suppressed |
| Xarelto | Rivaroxaban | 111 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 42 |
| Synthroid | Levothyroxine Sodium | 108 | 18 |
| Tramadol Hcl | Tramadol Hcl | 105 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 11 |
| Myrbetriq | Mirabegron | 101 | 11 |
| Olanzapine | Olanzapine | 99 | suppressed |
| Prednisone | Prednisone | 97 | 32 |
| Carvedilol | Carvedilol | 94 | 21 |
| Famotidine | Famotidine | 94 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 12 |
| Chlorthalidone | Chlorthalidone | 91 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 86 | suppressed |
| Lovastatin | Lovastatin | 83 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 23 |
| Levofloxacin | Levofloxacin | 78 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 77 | 12 |
| Midodrine Hcl | Midodrine Hcl | 77 | suppressed |
| Valsartan | Valsartan | 77 | 13 |
| Clonazepam | Clonazepam | 76 | 20 |
| Sucralfate | Sucralfate | 76 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 70 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 69 | suppressed |
| Meloxicam | Meloxicam | 69 | 20 |
| Spironolactone | Spironolactone | 69 | 17 |
| Fenofibrate | Fenofibrate | 68 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | suppressed |
| Januvia | Sitagliptin Phosphate | 62 | 15 |
| Lactulose | Lactulose | 62 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 19 |
| Digoxin | Digoxin | 61 | suppressed |
| Gemtesa | Vibegron | 61 | suppressed |
| Glimepiride | Glimepiride | 60 | 15 |
| Benazepril Hcl | Benazepril Hcl | 59 | 13 |
| Budesonide | Budesonide | 59 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 58 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 56 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 55 | suppressed |
| Ozempic | Semaglutide | 53 | 15 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 52 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 52 | suppressed |
| Glipizide Er | Glipizide | 51 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | suppressed |
| Latanoprost | Latanoprost | 50 | suppressed |
| Lorazepam | Lorazepam | 49 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 44 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 43 | suppressed |
| Lubiprostone | Lubiprostone | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 32 |
| Topiramate | Topiramate | 40 | suppressed |
| Cilostazol | Cilostazol | 39 | suppressed |
| Cephalexin | Cephalexin | 37 | 19 |
| Nystatin | Nystatin | 37 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Insulin Lispro | Insulin Lispro | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 28 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Cyclosporine | Cyclosporine | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Methazolamide | Methazolamide | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Prevacid | Lansoprazole | 23 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Clozapine | Clozapine | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 11 |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Niacin Er | Niacin | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Lumigan | Bimatoprost | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Ramelteon | Ramelteon | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Olanzapine Odt | Olanzapine | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Cefuroxime | Cefuroxime Axetil | 17 | 17 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $727.14 · 7 records | Axsome Therapeutics, Inc. | Auvelity, PAXLOVID, QULIPTA, REPATHA, Stimulan | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error